Abstract 401P
Background
Utidelone, a genetically engineered epothilone analogue, has been proved to be efficacious for advanced breast cancer. However, the effect of utidelone for breast cancer patients(pts) with brain metastasis has not been reported. This trial was to assess the efficacy and safety of utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer pts with brain metastasis.
Methods
HER2-negative breast cancer pts with brain metastasis were enrolled and Simon’s two-stage optimal trial design was used for this trial (NCT05781633). If more than 3 out of 13 pts show central nervous system (CNS) response, 30 more pts would be further enrolled. Utidelone (30mg/m2, iv, d1-5), and etoposide (100mg/m2, iv, d1-3) concurrently with bevacizumab (10mg/kg iv, d1) every 21 days for 6 cycles, with utidelone and bevacizumab maintenance until disease progression or unacceptable toxicity. The primary endpoint was CNS–objective response rate (ORR). Secondary endpoints include CNS-clinical benefit response (CBR), CNS-progression-free survival (PFS), ORR, PFS, CBR, overall survival (OS), and safety.
Results
17 female pts with a median age of 48 years (range 34-67) were enrolled from August 11, 2022 to March 22, 2023. 11 patients are evaluable for response with median cycles of 6 (2-8) , all of whom are still under treatment. CNS-ORR, CNS-CBR, ORR, CBR were 73% (8/11), 82% (9/11), 27% (3/11) and 55% (6/11), respectively, including a pt with PR for 8 cycles. PFS and OS have not been reached due to a short follow-up time. Therefore, the trial has met the criteria to enter the second stage. The major adverse event (AE) was peripheral neuropathy (PN), primarily classified as sensory. Grade 3 PN was seen in 9% (1/11) of the total patients. Most of the treatment-related AEs were grade 1 or 2 and were considered manageable and reversible. 1 pt experienced utidelone-related dose adjustment. No treatment-related death occurred.
Conclusions
Utidelone in combination with etoposide and bevacizumab has shown anti-tumor activity and manageable toxicity in breast cancer pts with brain metastasis, and a randomized control trial is warrantied.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tianjin Science and Technology Funding (18ZXXYSY00070); Tianjin Municipal Education Commission Funding(2016YD03); Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
359P - Unveiling the factors influencing exercise engagement in breast cancer patients: Insights from the early recovery phase
Presenter: Sujin Yeon
Session: Poster session 03
360P - Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
Presenter: Yue Chai
Session: Poster session 03
361P - A phase II study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer
Presenter: Jing Wu
Session: Poster session 03
362P - CYBERNEO trial: Update of results at 14 years of follow-up
Presenter: Syrine Ben Dhia
Session: Poster session 03
363P - High adipocytokines and IL-18bp serum levels are associated with lower objective response rate after neoadjuvant treatment in breast cancer patients with metabolic syndrome
Presenter: Larissa Mont'Alverne Arruda
Session: Poster session 03
365P - Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study
Presenter: Baocheng Wang
Session: Poster session 03
366P - Artificial intelligence (AI)-powered assessment of complete and intense human epidermal growth factor receptor 2 (HER2)-positive tumor cell proportion in breast cancer: Predicting fluorescence in situ hybridization (FISH) positivity and response to HER2-targeted therapy
Presenter: Minsun Jung
Session: Poster session 03
367P - Sentinel lymph node biopsy (SLNB) in patients with locally advanced breast cancer (LABC): Descriptive, inferential and survival analysis
Presenter: Johanna Espejo Niño
Session: Poster session 03
368P - Impact of PET-CT-determined sarcopenia on survival and pathological complete response in breast cancer patients with neoadjuvant chemotherapy
Presenter: Gözde Tahtaci
Session: Poster session 03
369P - The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum- based neoadjuvant chemotherapy
Presenter: Hadar Goldvaser
Session: Poster session 03